- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. (Pubmed Central) - Jun 28, 2020
Kaletra and traditional Chinese medicine played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and traditional Chinese medicine in the treatment of COVID-19.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, ibuprofen / Generic mfg., lopinavir/ritonavir / Generic mfg.
Review, Journal: Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. (Pubmed Central) - Jun 28, 2020
Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored...Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points• Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.• Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.• Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
- |||||||||| Arbidol (umifenovir) / Pharmstandard, lopinavir/ritonavir / Generic mfg.
Retrospective data, Journal, Monotherapy: Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19. (Pubmed Central) - Jun 28, 2020
Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.
- |||||||||| Flagyl (metronidazole) / SLA, ciprofloxacin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Journal: Pneumatosis intestinalis in COVID-19. (Pubmed Central) - Jun 28, 2020
PI involving the caecum and right colon has been described for HIV and Cytomegalovirus infections, but, to our best knowledge, never before in COVID-19. We hypothesise a multifactorial aetiopathogenesis for PI, with a possible role of the bowel wall damage and microbiota impairment due to SARS-CoV-2 infection, and we suggest a conservative management in the absence of symptoms.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Literature-based review of the drugs used for the treatment of COVID-19. (Pubmed Central) - Jun 28, 2020
This review concludes that the drugs mentioned above are having different properties and act differently in combating the COVID-19 viruses. Instead of single drug, combination of antivirals with different mechanism of action may be more effective and at the same time their adverse events should not be underestimated.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: What We Learned about COVID-19 So Far? Notes from Underground. (Pubmed Central) - Jun 27, 2020
Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to be the potential drug candidates in COVID-19 management. Despite these efforts, we still have much to learn regarding the transmission, treatment, and prevention of COVID-19.
- |||||||||| ibuprofen / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea. (Pubmed Central) - Jun 27, 2020
Patients treated with lopinavir/ritonavir had significantly shorter progression-free survival than those not receiving lopinavir/ritonavir. KCDC classification I clearly distinguished the improvement/stabilization group from the progression group of COVID-19 patients (AUC 0.817; 95% CI, 0.740-0.895).
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Review, Journal: Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. (Pubmed Central) - Jun 25, 2020
Finally, a very promising therapeutic drug, tocilizumab, is discussed; it is currently used to treat patients presenting COVID-19 pneumonia. Herein, we recapitulate these experimental studies to highlight the use of antiviral drugs for the treatment of SARS-Cov-2 disease.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Biomarker, Clinical, Journal: Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant? (Pubmed Central) - Jun 25, 2020
In severe forms, immune/inflammatory alterations reminiscent of disease forms like Macrophage Activation Syndrome (MAS) have been described, and therapeutic options other than anti-infective have been proposed and implemented, such as anti-inflammatory and anticoagulative agents. The thrombotic phenomena described in the pulmonary vascular bed of patients with severe COVID-19 suggest the administration of low-molecular weight heparin (LMWH) as standard measure in hospitalized patients with COVID-19.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Retrospective data, Journal: Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis. (Pubmed Central) - Jun 23, 2020
For adults with SARS, interferon was associated with reduced corticosteroid dose [weighted mean difference (WMD) = -0.14 g; 95% CI, -0.21 to -0.07] but had no effect on mortality (RR =0.72; 95% CI, 0.28 to 1.88); ribavirin did not reduce mortality (RR =0.68; 95% CI, 0.43 to 1.06) and was associated with high risk of severe adverse reactions; and oseltamivir had no effect on mortality (RR =0.87; 95% CI, 0.55 to 1.38)...There is no evidence showing the effectiveness of antiviral agents for children with COVID-19, and the clinical efficacy of existing antiviral agents is still uncertain. We do not suggest clinical routine use of antivirals for COVID-19 in children, with the exception of clinical trials.
- |||||||||| lopinavir/ritonavir / Generic mfg.
[VIRTUAL] Impact of PMTCT programmes on mother and child outcomes in Colombia (Abstract Sessions On-Demand Channel) - Jun 22, 2020 - Abstract #AIDS2020AIDS_1583;
This is the first report in Colombia of a nationwide HIV pregnant women and newborn cohort combined outcomes of PMTCT programmes. Our data confirmed that combining early diagnosis of HIV and referral to care in HIV centres results in few pregnancy-related complications, rare poor birth outcomes, and no vertical transmissions.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Influence of COVID-19 on Cerebrovascular Disease and its Possible Mechanism. (Pubmed Central) - Jun 19, 2020
Presently, effective drugs are lacking, although current studies have confirmed that drugs with therapeutic potential include redaciclovir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies...COVID-19 patient outcomes may also be complicated with acute stroke. This paper summarizes the influence of COVID-19 on cerebrovascular disease and discusses possible pathophysiological mechanisms to provide new angles for the prevention and diagnosis of this disease.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report. (Pubmed Central) - Jun 18, 2020
However, severe cases of COVID-19 pneumonia, or another novel infectious disease, could present at any moment and would be a continuing challenge to pursue appropriate measures. We need to be well prepared to secure healthcare workers from exposure to infectious diseases and nosocomial spread, as well as to provide necessary intensive care.
- |||||||||| hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment open: OUTCOV: OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome (clinicaltrials.gov) - Jun 18, 2020
P3, N=640, Recruiting,
We need to be well prepared to secure healthcare workers from exposure to infectious diseases and nosocomial spread, as well as to provide necessary intensive care. Not yet recruiting --> Recruiting
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Review, Journal: Potential therapeutic agents against COVID-19: What we know so far. (Pubmed Central) - Jun 18, 2020
This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Treatment options for COVID-19: The reality and challenges. (Pubmed Central) - Jun 18, 2020
The roles of teicoplanin (which inhibits the viral genome exposure in cytoplasm) and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are under investigation. Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II type I receptor blockers is advised for COVID-19 patients.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. (Pubmed Central) - Jun 18, 2020
Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II type I receptor blockers is advised for COVID-19 patients. An increase of Ct values was 0.9 per day in 2 cases of COVID-19 treated with lopinavir/ritonavir (LPV/r), an increase was 1.0 per day in 3 cases without LPV/r through illness day 1-10, indicating that LPV/r did not shorten the duration of SARS CoV-2 shedding.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Journal: Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). (Pubmed Central) - Jun 18, 2020
As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the "off-label" repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which have the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world's population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. (Pubmed Central) - Jun 18, 2020
Many antibiotics commonly used for the treatment of patients with COVID-19, for instance azithromycin, can also prolong QT interval...The article focuses on practical points and offers a point-of-care protocol for providers who are taking care of patients with COVID-19 in an inpatient and outpatient setting. The proposed protocol is taking into consideration that resources during the pandemic are limited.
|
